¹û¶³ÊÓƵ

Renowned experts bring decades of experience to ¹û¶³ÊÓƵ

Prominent global biotech investors including Canadian businessman Greg Bailey and British entrepreneur Jim Mellon have invested in ¹û¶³ÊÓƵ, a new company developing a pipeline of psychedelic drugs into licensed pharmaceutical medicines for treating psychiatric and neurological diseases.

World-first phase 1 trial will evaluate efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

¹û¶³ÊÓƵ today announced it has successfully completed an oversubscribed Series B financing, raising $80m (£58m) from venture capital (VC) investors to fund its promising research programmes.

¹û¶³ÊÓƵ’s Commercial Director Becky Verity explores the potential of digital therapeutics in mental health treatment.

We continue our look back at the heritage of the ¹û¶³ÊÓƵ Foundation’s ground-breaking research programmes and the potential for ¹û¶³ÊÓƵ, which leverages the Foundation’s knowledge and research capabilities through a close strategic partnership. This latest instalment of the Science Explained series examines the link between the acute psychedelic experience and longer-term changes.

Q&A with ¹û¶³ÊÓƵ CEO Cosmo Feilding Mellen

Dr. Laura Trespidi joins leadership team as Chief Development Officer

Partnership will capture behavioural and physiological signals and predictive biomarkers in ¹û¶³ÊÓƵ’s upcoming Phase 2 clinical trialsNew digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey

¹û¶³ÊÓƵ to collaborate with Lophora on researching New Clinical Entities (NCE’s)Broad collaboration with Lophora will further strengthen ¹û¶³ÊÓƵ’s world class management and R&D team